GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » Other Current Assets

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Other Current Assets : $47.7 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical Other Current Assets?

Ultragenyx Pharmaceutical's other current assets for the quarter that ended in Mar. 2024 was $47.7 Mil.

Ultragenyx Pharmaceutical's quarterly other current assets increased from Sep. 2023 ($46.0 Mil) to Dec. 2023 ($47.6 Mil) and increased from Dec. 2023 ($47.6 Mil) to Mar. 2024 ($47.7Mil).

Ultragenyx Pharmaceutical's annual other current assets declined from Dec. 2021 ($71.7 Mil) to Dec. 2022 ($68.9 Mil) declined from Dec. 2022 ($68.9 Mil) to Dec. 2023 ($47.6 Mil).


Ultragenyx Pharmaceutical Other Current Assets Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Other Current Assets Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.40 57.63 71.75 68.93 47.62

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.38 51.38 46.03 47.62 47.73

Ultragenyx Pharmaceutical Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Ultragenyx Pharmaceutical Other Current Assets Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Executives
Emil D Kakkis director, 10 percent owner, officer: President & CEO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg officer: CBO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn officer: Chief Financial Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga officer: Controller and PAO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris officer: EVP & Chief Commercial Officer 60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion officer: See Remarks C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer officer: EVP and General Counsel 60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang officer: SVP and Chief Tech Ops Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier officer: CFO & Executive Vice President C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp officer: CFO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949